NCT07814313

Brief Summary

This study will investigate how aging and spinal cord injury (SCI) affect the transmission and plasticity of the corticospinal and reticulospinal tracts, which are important pathways for motor control. The study includes two experiments. Experiment 1 will assess corticospinal and reticulospinal tract transmission to lower-limb muscles in older adults with and without SCI. Experiment 2 will examine how aging and spinal cord injury affect the body's ability to strengthen nerve pathways involved in movement. The investigators will compare two pathways that help control leg movement, the corticospinal and reticulospinal pathways, to determine whether aging affects these pathways differently and whether spinal cord injury has a greater effect on the corticospinal pathway.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
61mo left

Started Aug 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Aug 2025Sep 2031

Study Start

First participant enrolled

August 28, 2025

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

September 1, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 10, 2026

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2030

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2031

Last Updated

September 10, 2026

Status Verified

September 1, 2026

Enrollment Period

5.1 years

First QC Date

September 1, 2026

Last Update Submit

September 9, 2026

Conditions

Keywords

Spinal cord injury (SCI)agingmotor controlmotor recoveryplasticity

Outcome Measures

Primary Outcomes (3)

  • Motor evokoed potential

    Transcranial magnetic stimuli (TMS) will be delivered from a Magstim 200 stimulator (Magstim Company) through a double-cone coil with a monophasic current waveform. TMS will be delivered to the optimal scalp position for activation of upper or lower limb muscles. The optimal scalp position will be determined by moving the coil in small steps along the arm/leg muscle representation of the primary motor cortex to find the region where the largest MEP can be evoked with the minimum intensity in the targeted muscles. The muscles to be activated will be upper limb muscles such as deltoid, biceps, triceps, extensor carpi radialis, flexor carpi radialis and/or first dorsal interosseous; lower limb muscles such as quadriceps, hamstrings, tibialis anterior, soleus, and/or abductor hallucis muscles. Only the authorized research team will use the device and the investigator will comply with USFDA requirements for monitoring, records and reports. The research team will not market or promote the

    Periprocedural

  • MVC

    Individuals will perform a maximum voluntary contraction (MVC) of the targeted muscles through surface electrodes secured to the skin over the belly of each muscle (Ag-AgCl, 10 mm diameter). The signals will be amplified, filtered (20-1000 Hz), and sampled at 10 kHz for offline analysis.

    Periprocedural

  • StartReact

    The StartReact response will allow us make inferences about the contribution of the reticulospinal tract to spasticity. The StartReact response will be tested using a previously described paradigm in humans with and without SCI. Here, participants will be asked to observe a light-emitting diode (LED) located \~1 m in front of the participants' head. When the LED will illuminate (20 ms), individuals will be asked to perform an isometric elbow, knee and/or ankle flexion or an isometric elbow, knee and/or ankle extension as fast as possible. We will measure the visual reaction time (VRT) as the time from cue to onset of the EMG burst in the elbow muscles after the LED presentation. In some trials, the LED will be presented with either a quiet acoustic stimulus (80 dB, 500 Hz, 50 ms) or a startling acoustic stimulus (SAS, 120 dB, 500 Hz, 50 ms) delivered through a headphone. The time delay between the presentation of the quiet acoustic stimulus and the onset of the EMG response refer as th

    Periprocedural

Study Arms (2)

healthy control

Other: CST PASOther: RST PASOther: sham PAS

spinal cord injury

Other: CST PASOther: RST PASOther: sham PAS

Interventions

RST PASOTHER

transcranial magnetic stimulation and peripheral nerve stimulation are given at almost the same time to target brainstem-to-spinal cord connections

healthy controlspinal cord injury
CST PASOTHER

transcranial magnetic stimulation and peripheral nerve stimulation are given at almost the same time to target brain-to-spinal cord connections

healthy controlspinal cord injury

the setup will look and feel the same to the participant as the CST PAS or RST PAS. But one or both of the stimulations is not actually delivered, or it is delivered in a way that does not affect the participant

healthy controlspinal cord injury

Eligibility Criteria

Age19 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Vulnerable populations, including children (\<18 years) and pregnant women, will be excluded from this study.

You may qualify if:

  • Male and females between 19-85 years;
  • Chronic SCI (≥ 1 years post-injury);
  • T10 or above - American Spinal Injury Association (AIS) Grade C, or D;
  • Ability to perform a small voluntary ankle dorsiflexion, knee extension, and ankle plantarflexion (as detected by presence of voluntary EMG activity in the rectus femoris, tibialis anterior, and soleus muscles) with at least one leg;
  • Ability to tolerate standing position;
  • Ability to initiate at least one step without the assistance of a therapist;
  • Male and females (19-85 years);
  • Able to perform dorsiflexion;
  • Able to walk.

You may not qualify if:

  • Uncontrolled medical problems including pulmonary, cardiovascular, or orthopedic disease;
  • Any debilitating disease before the SCI that caused exercise intolerance;
  • Premorbid, ongoing major depression or psychosis, altered cognitive status;
  • History of head injury or stroke;
  • Pacemaker;
  • Metal plate in skull;
  • History of seizures;
  • Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold, such as antipsychotic drugs (chlorpromazine, clozapine) or tricyclic antidepressants;
  • Pregnancy;
  • Ongoing cord compression or a syrinx in the spinal cord or spinal cord disease, such as spinal stenosis, spina bifida or herniated cervical disk;
  • implanted defibrillators or implanted neurostimulators;
  • have large ischaemic scars;
  • diagnosed sleep deprivation.
  • \- Same as for subjects with SCI.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shirley Ryan Abilitylab

Chicago, Illinois, 60611, United States

RECRUITING

MeSH Terms

Conditions

Spinal Cord Injuries

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and Injuries

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Scientific Chair, Arms + Hands AbilityLab

Study Record Dates

First Submitted

September 1, 2026

First Posted

September 10, 2026

Study Start

August 28, 2025

Primary Completion (Estimated)

September 30, 2030

Study Completion (Estimated)

September 30, 2031

Last Updated

September 10, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations